£520.00

The 2023-2028 Outlook for Schizophrenia Treatments in the United States

Subjects

Price data last checked 17 day(s) ago - will refresh soon

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£520 today · cheaper than every other day in the last 3 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 74 days · 74 data points (no recent data)

Historical

Generating forecast…

Price Distribution

Price distribution over 74 days • 1 price levels

Days at Price

Price Analysis

Most common price: £520 (74 days, 100.0%)

Price range: £520 - £520

Price levels: 1 different prices over 74 days

Description

This study covers the latent demand outlook for schizophrenia treatments across the states and cities of the United States. Latent demand (in millions of U.S. dollars), or potential industry earnings (P.I.E.) estimates are given across some 12,600 cities in the United States. For each city in question, the percent share the city is of its state and of the United States as a whole is reported. These comparative benchmarks allow the reader to quickly gauge a city vis-à-vis others. This statistical approach can prove very useful to distribution and/or sales force strategies. Using econometric models which project fundamental economic dynamics within each state and city, latent demand estimates are created for schizophrenia treatments. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of schizophrenia treatments as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include AbbVie, Alkermes, Allergan, Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Gedeon Richter, Johnson & Johnson, Merz Pharma., Novartis, Otsuka Holdings Company, Pfizer, PsychoGenics, Inc., Sumitomo Dainippon Pharma Company, and Vanda Pharmaceuticals. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B0BLPZBN7G
Category: Books > Subjects
Domain: Amazon UK
Release Date: 26 October 2022
Listed Since: 10 November 2022

The 2023-2028 Outlook for Schizophrenia Treatments in the United States

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Schizophrenia Drugs in the United States

The 2023-2028 Outlook for Schizophrenia Therapeutics in Japan

Schizophrenia Treatment - The New Facets

Schizophrenia in the 21st Century

New Approaches to the Management and Diagnosis of Schizophrenia

Schizophrenia: A Contemporary Introduction (Routledge Introductions to Contemporary Psychoanalysis)

A Phenomenological Interpretation of Schizophrenia: Subjectivation, Framework and Perspective

Negative and Cognitive Symptoms in Schizophrenia (Comprehensive Approach to Psychiatry, 3)

Schizophrenie: Dopaminrezeptoren und Neuroleptika

Social Skills Training for Schizophrenia, Third Edition: A Step-by-Step Guide

Schizophrenia

Literatur und Schizophrenie: Theorie Und Interpretation Eines Grenzgebiets: 45 (Deutsche Texte)

Outcome and Innovation in Psychological Treatment of Schizophrenia

Schizophrenic Psychology: New Research

Cognition in Schizophrenia and Paranoia: The Integration of Cognitive Processes (Psychology Revivals)

Gespräche mit Schizophrenen: Kohärenzbrüche und der Versuch ihrer Überbrückung

Die Darstellung von Schizophrenie in der Literatur. E.T.A. Hoffmann und Robert Louis Stevenson

Neuroproteomics as a Tool for Understanding Schizophrenia: 1400 (Advances in Experimental Medicine and Biology, 1400)

Role of Histamine H3 receptor ligands in Experimental Schizophrenia

Obsessive-Compulsive Symptoms in Schizophrenia

Neuroimaging in Schizophrenia

Expressed Emotion, Quality of Life, and Burden of Caregivers: A Study on Schizophrenia and Bipolar Affective Disorder in Indian Context